BLENOXANE
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Jul 1973
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 16h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BLENOXANE is a legacy injectable small-molecule chemotherapy agent approved in 1973 by Bristol Myers Squibb. The specific mechanism of action and therapeutic indications are not detailed in available data, but the product represents a classic cytotoxic agent from the early chemotherapy era. It is administered via injection and remains in active use despite its age.
LOE Approaching
As a legacy product approaching loss of exclusivity, team size is likely stable or contracting; commercial focus shifts toward managed care and generics containment rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on BLENOXANE offers limited growth but stable, specialized experience in legacy product management and generic competition strategy. This role suits professionals interested in cost containment, managed care dynamics, and defending market position in oncology rather than launching new therapies.
Brand ManagerField Sales Representative
Worked on BLENOXANE at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.